Business-and-Finance

Aakaar Medical Technologies IPO GMP: Know Before You Invest

Aakaar Medical Technologies IPO GMP: Know Before You Invest
By - Roshni Singh 9 min read 0 views


Aakaar Medical Technologies IPO GMP: A Complete Investor Guide

Thinking about investing in the Aakaar Medical Technologies IPO GMP? If yes, this easy-to-understand guide will help you understand everything — from IPO dates and lot sizes to GMP updates, financials, and future prospects.

 This SME IPO aims to raise ₹27 crore through a fresh issue of 37.50 lakh shares, with a price band of ₹68 to ₹72 per share. The company, founded in 2013, offers a wide range of aesthetic medical devices catering to dermatologists, plastic surgeons, and cosmetologists. Its product portfolio includes skincare, hair care, laser devices, and medical-grade aesthetic solutions, sourced from countries like South Korea, Spain, and Italy.






📌 What Is the Aakaar Medical Technologies IPO?

Aakaar Medical Technologies Limited is coming out with an SME IPO on the NSE SME platform. The company plans to raise approximately ₹27 crore through a fresh issue of 37.5 lakh shares. This issue follows the book-building method, which is common in IPOs where investors bid within a price range.

  • Price Band: ₹68–₹72 per share

  • Lot Size: 1,600 shares per lot

  • Minimum Investment (Retail): ₹1,15,200 (at the upper end)

  • Total Issue Size: ₹27 crore

The high minimum investment reflects the SME nature of this IPO, which often involves higher risk but also potentially higher listing gains.




🗓️ Important IPO Dates to Remember

Mark these dates in your calendar if you're planning to apply for this IPO:

Event

Date

IPO Opens

June 20, 2025

IPO Closes

June 24, 2025

Allotment Finalization

June 25, 2025

Refunds Begin

June 26, 2025

Shares Credited in Demat

June 26, 2025

Listing Date (NSE SME)

June 27, 2025

So, if you're planning to apply, make sure to place your bid between June 20 and June 24, 2025.




🧪 What Does Aakaar Medical Do?

Founded in 2013, Aakaar Medical Technologies is a healthcare company focused on aesthetic medical devices. It serves a niche but growing market in India, especially targeting:

  • Dermatologists

  • Plastic surgeons

  • Cosmetology and beauty clinics

Their product portfolio includes:

✅ For Skin Care

  • Home-use kits, fillers, and professional serums

✅ Hair Care

  • Hair growth serums, oral tablets, and transplant equipment

✅ Aesthetic Dermatology Tools

  • Tattoo removal lasers, rejuvenation machines, advanced skin treatment devices

✅ Specialty Products

  • Devices for incontinence and intimate wellness

They don’t manufacture in-house; instead, they import products from Korea, Italy, Spain, and Austria, which helps maintain quality but adds supply chain dependency.




📊 Financial Performance Snapshot (FY 2024 vs. FY 2025)

The company has shown promising growth in recent years. Here’s a quick financial comparison:

  • Total Assets: ₹34.01 lakh → ₹51.85 lakh

  • Revenue: ₹46.27 lakh → ₹61.76 lakh

  • Net Profit: ₹2.87 lakh → ₹6.04 lakh

  • Net Worth: ₹12.53 lakh → ₹23.20 lakh

Their net profit more than doubled within a year, indicating strong operational performance.

However, it’s important to note that cash flow from operations was negative (–₹540 lakh) due to high inventory buildup. Fortunately, they managed to cover it with a funding inflow of over ₹10 crore, which they plan to utilize for working capital and general corporate purposes.




💹 Aakaar Medical IPO GMP (Grey Market Premium) Today

As of June 17, 2025, the Aakaar Medical IPO GMP is ₹0. That means there’s currently no premium in the unofficial grey market. It indicates that demand is neutral and listing may be close to the issue price (₹72).

📌 What does this mean for you?
GMPs are just indicators — they fluctuate daily and are influenced by investor sentiment. While ₹0 GMP isn’t negative, it suggests you should wait and monitor the trend daily before making a final investment decision.




⚖️ Strengths and Risks

Let’s look at both sides of the coin.

✅ Strengths

  • Strong leadership with experience in the aesthetics space

  • Diversified product range (skin, hair, and wellness devices)

  • Wide distribution network across India through channel partners

  • Rising revenues and profitability

⚠️ Risks

  • No manufacturing unit – 100% reliance on foreign suppliers

  • Currency fluctuations and import costs can impact margins

  • SME segment volatility – not suitable for extremely risk-averse investors

  • Limited comparable listed peers, making valuation analysis difficult




🧑‍💼 Who’s Behind the IPO?

  • Promoters:

    • Dilip Ramesh Meswani

    • Bindi Dilip Meswani

    • They currently hold 91.11% of the pre-issue equity

  • Registrar:Bigshare Services Pvt. Ltd.

  • Lead Manager:Indorient Financial Services Ltd.

These entities will handle the application process, allotment, and investor services.




❓ Frequently Asked Questions (FAQ)

Q1: What is the minimum investment for retail investors?
A: 1 lot = 1,600 shares = ₹1,15,200 at ₹72 per share.

Q2: When is the Aakaar Medical Technologies IPO open for bidding?
A: It opens on June 20 and closes on June 24, 2025.

Q3: What is the price band of the IPO?
A: The price band is ₹68 to ₹72 per equity share.

Q4: What is the listing date of Aakaar Medical IPO?
A: The expected listing date is June 27, 2025.

Q5: What is the current GMP of the IPO?
A: The GMP is ₹0 as of June 17, 2025.




✅ Final Verdict: Should You Apply?

The Aakaar Medical Technologies IPO GMP offers an opportunity to invest in a niche segment of aesthetic medical devices, which is growing steadily in India. The company has shown consistent financial growth, and its diversified product range gives it a competitive edge.

However, the lack of manufacturing capabilities and reliance on imported products makes it vulnerable to global disruptions.

With the current GMP at ₹0, investors should:

  • Track GMP updates daily

  • Assess risk appetite

  • Focus on long-term fundamentals

If you're comfortable with SME IPOs and want exposure to a niche healthcare sector, this IPO might be worth considering.